Open Access

Preclinical antitumor activity of SST0116CL1: A novel heat shock protein 90 inhibitor

  • Authors:
    • Loredana Vesci
    • Ferdinando Maria Milazzo
    • Valeria Carollo
    • Silvia Pace
    • Giuseppe Giannini
  • View Affiliations

  • Published online on: August 1, 2014     https://doi.org/10.3892/ijo.2014.2575
  • Pages: 1421-1429
  • Copyright: © Vesci et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

4-Amino substituted resorcino-isoxazole (SST0116CL1) (property of Sigma-Tau Research Switzerland S.A.) is a potent, second generation, small-molecule heat shock protein 90 inhibitor (Hsp90i). SST0116CL1 binds to the ATP binding pocket of Hsp90, and interferes with Hsp90 chaperone function thus resulting in client protein degradation and tumor growth inhibition. The aim of the study was to assess SST0116CL1 in various solid and haematological tumors. The antitumor properties of SST0116CL1 were assessed using in vitro cell proliferation and client protein degradation assays and in vivo different tumor xenograft models. Pharmacokinetic (PK) data were also generated in tumor-bearing mice to gain an understanding of optimal dosing schedules and regimens. SST0116CL1 was shown to inhibit recombinant Hsp90α and to induce the destabilization of different client proteins, often overexpressed and constitutively activated in different types of hematological or solid human tumors. In preclinical in vivo studies, it was revealed to induce antitumor effects in murine models of leukemia and of gastric and ovarian carcinoma. A modulation of PD biomarkers in terms of downregulation of Hsp90 client proteins in tumor-bearing mice was found. SST0116CL1 is a new clinical candidate for cancer therapy. The antitumor property of SST0116CL1, likely due to direct inhibition of the Hsp90 enzymatic activity, may prove to be a critical attribute as the compound enters phase I clinical trials.
View Figures
View References

Related Articles

Journal Cover

October 2014
Volume 45 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Vesci, L., Milazzo, F.M., Carollo, V., Pace, S., & Giannini, G. (2014). Preclinical antitumor activity of SST0116CL1: A novel heat shock protein 90 inhibitor. International Journal of Oncology, 45, 1421-1429. https://doi.org/10.3892/ijo.2014.2575
MLA
Vesci, L., Milazzo, F. M., Carollo, V., Pace, S., Giannini, G."Preclinical antitumor activity of SST0116CL1: A novel heat shock protein 90 inhibitor". International Journal of Oncology 45.4 (2014): 1421-1429.
Chicago
Vesci, L., Milazzo, F. M., Carollo, V., Pace, S., Giannini, G."Preclinical antitumor activity of SST0116CL1: A novel heat shock protein 90 inhibitor". International Journal of Oncology 45, no. 4 (2014): 1421-1429. https://doi.org/10.3892/ijo.2014.2575